Longevity of post-explantation systemic symptom improvement and potential etiologies: findings from the ASERF systemic symptoms in women–biospecimen analysis …
C Glicksman, P McGuire, M Kadin… - Aesthetic surgery …, 2023 - academic.oup.com
Aesthetic surgery journal, 2023•academic.oup.com
Abstract Background Breast Implant Illness (BII) describes a variety of symptoms reported by
patients with breast implants. Biospecimens data revealed minimal statistical differences
between BII and non-BII cohorts. Baseline analysis of PROMIS data demonstrated
significant differences between the BII cohort and the 2 control cohorts. Objectives This study
was designed to determine if patients in the BII cohort obtained any symptom improvement
after explantation, whether symptom improvement was related to the type of capsulectomy …
patients with breast implants. Biospecimens data revealed minimal statistical differences
between BII and non-BII cohorts. Baseline analysis of PROMIS data demonstrated
significant differences between the BII cohort and the 2 control cohorts. Objectives This study
was designed to determine if patients in the BII cohort obtained any symptom improvement
after explantation, whether symptom improvement was related to the type of capsulectomy …
Background
Breast Implant Illness (BII) describes a variety of symptoms reported by patients with breast implants. Biospecimens data revealed minimal statistical differences between BII and non-BII cohorts. Baseline analysis of PROMIS data demonstrated significant differences between the BII cohort and the 2 control cohorts.
Objectives
This study was designed to determine if patients in the BII cohort obtained any symptom improvement after explantation, whether symptom improvement was related to the type of capsulectomy, and which symptoms improved.
Methods
A prospective blinded study enrolled 150 consecutive patients divided equally into 3 cohorts. Baseline demographic data and a systemic symptoms survey, including PROMIS validated questionnaires, were obtained at baseline, 3 to 6 weeks, 6 months, and 1 year.
Results
A total of 150 patients were enrolled between 2019 and 2021. Follow-up at 1 year included 94% of the BII cohort and 77% of non-BII and mastopexy cohorts. At 1 year, 88% of patients showed at least partial symptom improvement, with a reduction of 2 to 20 symptoms. The PROMIS score in the BII cohort decreased at 1 year for anxiety, sleep disturbances, and fatigue. Systemic symptom improvement was noted out to 1 year in the BII cohort regardless of the type of capsulectomy performed.
Conclusions
Parts 1–3 in this series concluded that there were no consistent differences in biospecimen results between the cohorts. Unlike the data observed in the biospecimen analysis, BII patients had heightened symptoms and poorer PROMIS scores at baseline compared to the control cohorts. The reduction of negative expectations and a potential nocebo effect could contribute to this improvement.
Level of Evidence: 4
Oxford University Press